Georgia State University Develops Universal Flu Vaccine
Analysis based on 6 articles · First reported Apr 03, 2026 · Last updated Apr 10, 2026
The development of a novel influenza vaccine platform by Georgia State University could lead to more effective and broader protection against influenza strains, potentially reducing the need for frequent vaccine reformulations. This breakthrough could significantly impact the biotechnology and pharmaceutical industries by opening new avenues for universal vaccine development and delivery methods.
Researchers at Georgia State University have developed a novel vaccine platform utilizing cell-derived extracellular vesicles (EVs) to display influenza hemagglutinins (HAs) in an inverted manner. This design presents the conserved HA stalk to the immune system, inducing broad, cross-protective immunity against various influenza virus infections while hiding the highly variable HA head. In mouse models, intranasal immunization with this multiple HA-EV vaccine elicited cross-reactive antibodies and robust cellular immune responses, providing complete protection against lethal H7N9 and H5N1 challenges. The study, funded by the Norway — Norwegian Institute of Public Health of the United States — National Institutes of Health, shows promise for developing universal influenza vaccines that target a mucosal route, addressing the urgent need for effective mucosal vaccination strategies beyond existing options like Live attenuated influenza vaccine.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard